Valuing Genomics Ingena

Valuing Genomics Ingena Ingena commissioned deloitte access economics to conduct research which will provide a snapshot of the potential value of genomics on healthcare in australia by profiling a suite of case study applications across the screening, diagnosis, and treatment stages of the care continuum. Deloitte access economics’ research for the industry genomics network alliance (ingena) provides a snapshot of the potential value of genomics on healthcare in australia by profiling a suite of case study applications across the screening, diagnosis, and treatment stages of the care continuum.

Valuing Genomics Ingena “valuing the impact of genomics on healthcare in australia”, undertaken for ingena by deloitte access economics, features five case studies profiling potential applications of genomics across the screening, diagnosis, and treatment stages of the care continuum. Join us to hear about the case studies, the key outcomes and understand the opportunities genomics holds for individuals, families and carers, society, and our health system. Genomics and precision medicine have the potential to shift our health system from reactive to preventive something i’m deeply passionate about. this isn’t just innovation for its own sake. We share a vision for australia’s leadership in the adoption of genomics in healthcare including: better health outcomes; healthcare value and affordability; and a trusted, equitable and ethical genomics ecosystem.

Valuing Genomics Ingena Genomics and precision medicine have the potential to shift our health system from reactive to preventive something i’m deeply passionate about. this isn’t just innovation for its own sake. We share a vision for australia’s leadership in the adoption of genomics in healthcare including: better health outcomes; healthcare value and affordability; and a trusted, equitable and ethical genomics ecosystem. Today ingena has published the report of the event that summarises the discussions and the proposed actions needed to achieve these outcomes.rather than just a vision, it was focused on tangible. Ingena has continued to evolve throughout our second year. 20 of our 21 members renewed membership with ingena for the mar 2022 – feb 2023 membership period, representing the genomics value chain from diagnostics and pathology, data analysis, and through to pharmaceuticals. Ingena is a single voice for australian industry partners contributing to the rapidly developing field of genomics. alliance partners share a vision for australia’s leadership in the adoption of genomics in healthcare. Genomic data in australia, the first industry led report on data sharing and the challenges facing governance around genomic data, is published by the industry genomics network alliance (ingena).

Valuing Genomics Ingena Today ingena has published the report of the event that summarises the discussions and the proposed actions needed to achieve these outcomes.rather than just a vision, it was focused on tangible. Ingena has continued to evolve throughout our second year. 20 of our 21 members renewed membership with ingena for the mar 2022 – feb 2023 membership period, representing the genomics value chain from diagnostics and pathology, data analysis, and through to pharmaceuticals. Ingena is a single voice for australian industry partners contributing to the rapidly developing field of genomics. alliance partners share a vision for australia’s leadership in the adoption of genomics in healthcare. Genomic data in australia, the first industry led report on data sharing and the challenges facing governance around genomic data, is published by the industry genomics network alliance (ingena).